Deal record
Interpace Biosciences, Inc. / 1315 Capital, Ampersand Capital Partners
Minority investment · Recorded status: Announced
Verified findings
Facts and causal attributions that have passed evidence review and remain backed by their reviewed sources.
No verified findings published yet.
Last reviewed: Unknown · Record updated: Sept. 27, 2026
Recorded deal
Database fields for this transaction. A recorded status is not an independently verified closing fact, and a recorded date or value is not a verified one.
- Transaction type
- Minority investment
- Recorded status
- Announced
- Announced
- Jan. 13, 2020
- Closed
- Unknown
- Recorded value
- $20 million
- Ownership percent
- Unknown
Recorded parties
Entities named on this deal record, each with the role it was recorded under.
- TargetInterpace BiosciencesCompany
- Acquirer1315 CapitalInvestment firm
- AcquirerAmpersand Capital PartnersInvestment firm
- Sponsor1315 CapitalInvestment firm
- SponsorAmpersand Capital PartnersInvestment firm
Record sources
Recorded provenance. These sources have not independently verified the deal fields or every party role.
- Interpace Biosciences Enters into Agreement for $20 Million Investment from 1315 Capital and Ampersand Capital Partners
Ampersand Capital Partners · Published: Jan. 6, 2020 · Retrieved: Sept. 11, 2026 · Recorded, not verified
About this record
Verified findings have passed evidence review and stay published only while their reviewed evidence matches what currently exists. Findings listed above are findings about this deal; they do not verify the deal’s other recorded fields.
Everything under Recorded deal, Recorded parties, and Recorded ownership is database record data. Record origin and independent verification are separate questions. Where a recorded field and a verified finding disagree, both are shown as they stand. Nothing here reconciles them.